Fouz Hassan¹*, Batoul Mohammad¹, Kheirbek Majed² and Ali Salim²

¹Department of Dermatology, Tishreen University Hospital, Latakia, Syria
²Faculty of Medicine, Tishreen University, Latakia, Syria

*Corresponding Author: Fouz Hassan, Department of Dermatology, Tishreen University Hospital, Latakia, Syria.

Received: June 11, 2021; Published: 00-00

Citation: Fouz Hassan., et al. “Neoadjuvant Intralesional Treatment of SCC with 5-FU: A Case Report". Acta Scientific Microbiology 5.9 (2021): 38-41.

Abstract

5-Fluorouracil (5-FU) has been used topically and intralesional to treat lesions related to squamous cell carcinoma (SCC) such as actinic keratosis, Bowen’s disease, and keratoacanthoma.

This case of squamous cell carcinoma (SCC) that was successfully treated with intralesional 5-FU, provides a possible therapeutic option for patients who are not good surgical.

Keywords: 5-Fluorouracil (5-FU); Squamous Cell Carcinoma; Keratoacanthoma

Bibliography

1. “Detailed guide: skin cancer: nonmelanoma: what are the key statistics about nonmelanoma skin cancer?” American Cancer Society (2007).
2. Howell JY and Ramsey ML. “Cancer, Squamous Cell, Skin”. (2017).
3. Kraus Stephen., et al. “Intratumoral chemotherapy with fluorouracil/epinephrine injectable gel: A nonsurgical treatment of cutaneous squamous cell carcinoma”. Journal of the American Academy of Dermatology 3 (1998): 438-442.
4. Goette DK. “Topical chemotherapy with 5-fluorouracil”. Journal of the American Academy of Dermatology 4 (1981): 633-649.
5. Odom RB and Goette DK. “Treatment of keratoacanthomas with intralesional fluorouracil”. Archives of Dermatology 114 (1978): 1779-1783.
6. Goette DK and Odom RB. “Successful treatment of keratoacanthoma with intralesional fluorouracil”. Journal of the American Academy of Dermatology 2 (1980): 212-216.
7. Eubanks SW., et al. “Treatment of multiple keratoacanthomas with intralesional fluorouracil”. Journal of the American Academy of Dermatology 7 (1982): 126-129.
8. Parker CM and Hanke CW. “Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil”. Journal of the American Academy of Dermatology 14 (1986): 770-777.
9. Miller BH., et al. “Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil injectable gel”. Journal of the American Academy of Dermatology 36 (1997): 72-77.
10. Love WE., et al. “Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review”. Archives of Dermatology 145 (2009): 1431-1438.
11. Arits AH., et al. “Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial”. Lancet Oncology 14 (2013): 647-654.
12. , et al. “Treatment of scc with intralesional 5-fu”. Dermatology Surgery 29 (2003).
13. Midena E., et al. “Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil”. The British Journal of Ophthalmology3 (2000): 268-272.

Copyright: © 2021 Fouz Hassan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.